Synlogic (NASDAQ:SYBX) Stock Price Crosses Below 50 Day Moving Average – Here’s What Happened

Synlogic, Inc. (NASDAQ:SYBXGet Free Report)’s share price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.64 and traded as low as $0.60. Synlogic shares last traded at $0.69, with a volume of 6,170 shares changing hands.

Synlogic Stock Down 1.4%

The firm has a 50 day moving average of $0.64 and a 200 day moving average of $0.83. The firm has a market cap of $8.07 million, a PE ratio of -2.65 and a beta of 0.56.

Hedge Funds Weigh In On Synlogic

Several institutional investors have recently bought and sold shares of SYBX. DRW Securities LLC purchased a new stake in shares of Synlogic during the fourth quarter worth $27,000. Citadel Advisors LLC purchased a new stake in shares of Synlogic during the third quarter worth $49,000. Finally, Renaissance Technologies LLC lifted its position in shares of Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 46,117 shares in the last quarter. Hedge funds and other institutional investors own 63.40% of the company’s stock.

Synlogic Company Profile

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Featured Stories

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.